Minerva Neurosciences (NERV) Total Liabilities (2013 - 2026)

Minerva Neurosciences has reported Total Liabilities for 14 years, with the latest figure at $343.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 453.83% year-over-year to $343.1 million; the trailing twelve-month figure through Mar 2026 stood at $343.1 million (up 453.83% YoY), and the FY2025 full-year result was $233.8 million, up 272.0% from the prior year.
• Total Liabilities for Q1 2026 stood at $343.1 million, up from $233.8 million in the prior quarter.
• The five-year high for Total Liabilities was $343.1 million in Q1 2026, with the low at $61.9 million in Q1 2025.
• Historically, Total Liabilities has averaged $99.4 million across 5 years, with a median of $75.1 million in 2022.
• Annual changes were most pronounced in 2025 — Total Liabilities sank 31.12% — and 2026, when it surged 453.83%.
• Minerva Neurosciences' Total Liabilities stood at $75.1 million in 2022, then gained by 13.64% to $85.4 million in 2023, then dropped by 26.38% to $62.8 million in 2024, then surged by 272.0% to $233.8 million in 2025, then surged by 46.77% to $343.1 million in 2026.
• The last three Total Liabilities figures came in at $343.1 million (Q1 2026), $233.8 million (Q4 2025), and $62.7 million (Q3 2025), per Business Quant data.